A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

Stopped With recent advances in immunotherapy scientific question not significant

Conditions

• Melanoma

Interventions

• DRUG: sunitinib
• DRUG: nivolumab

Sponsor

California Pacific Medical Center Research Institute

Collaborators

• [object Object]